title: CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.
abstract: Primary CD30(+) cutaneous T-cell lymphomas (CTCLs) represent a spectrum of non-Hodgkin's lymphomas (NHLs) that have been well defined at the clinical, histologic, and immunologic level. This group, which includes 2 main entities (large cell lymphoma and lymphomatoid papulosis [LyP]) and borderline cases, is characterized by the expression of CD30 antigen by neoplastic large cells at presentation, possible spontaneous regression of the skin lesions, and generally favorable clinical course. Although the functional relevance of CD30 and its natural ligand (CD30L) expression in most cases of NHL is presently undefined, previous studies indicate that CD30L is likely to mediate reduction of proliferation in CD30(+) anaplastic large-cell NHL. No information is currently available concerning the expression of CD30L in primary CD30(+) CTCLs. In this study, we investigated the immunophenotypic and genotypic expression of CD30 and CD30L in different developmental phases of skin lesions (growing v spontaneously regressing). By immunohistochemistry, CD30L expression was detected in regressing lesions only; by molecular analysis, the expression of CD30L was clearly higher in regressing lesions than in growing ones. CD30L, while expressed by some small lymphocytes, was most often coexpressed by CD30(+) neoplastic large cells, as demonstrated by 2-color immunofluorescence and by immunohistochemistry on paraffin sections. Taken together, these data suggest that CD30-CD30L interaction may play a role in the pathobiology of primary cutaneous CD30(+) lymphoproliferative disorders. In particular, CD30L (over)expression might have a major role in the mechanism of self-regression of skin lesions, the most distinctive clinical feature of this cutaneous lymphoma subtype.
authors.affiliation: Department of Dermatology, University of Florence Medical School, Florence, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: C
authors.initials: C
authors.lastname: Manuelli
authors.forename: N
authors.initials: N
authors.lastname: Pimpinelli
authors.forename: C
authors.initials: C
authors.lastname: Mavilia
authors.forename: E
authors.initials: E
authors.lastname: Maggi
authors.forename: M
authors.initials: M
authors.lastname: Santucci
authors.forename: B
authors.initials: B
authors.lastname: Bianchi
authors.forename: P
authors.initials: P
authors.lastname: Cappugi
authors.forename: B
authors.initials: B
authors.lastname: Giannotti
authors.forename: M E
authors.initials: ME
authors.lastname: Kadin
mesh_terms: D000328:Adult; D000368:Aged; D053285:CD30 Ligand; D002455:Cell Division / Q000276:immunology; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology*; D008024:Ligands; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology*; D008875:Middle Aged; D009365:Neoplasm Regression, Spontaneous / Q000276:immunology; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology
chemical_list: D053285:CD30 Ligand; D017730:Ki-1 Antigen; D008024:Ligands; D008562:Membrane Glycoproteins; C505774:TNFSF8 protein, human